BRD9 Antibody Polyclonal

• Description :

  BRD9 Antibody Polyclonal_x000D_ Catalog number: B2016894_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 10 µL_x000D_ Molecular Weight or Concentration: 85 kDa_x000D_ Supplied as: Solution_x000D_ Applications: a molecular tool for various biochemical applications_x000D_ Storage: -20¬∞C_x000D_ Keywords: PRO9856, LAVS3040_x000D_ Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MŒ©-cm) and are filtered through 0.22 um._x000D_ _x000D_ References:_x000D_ 1: Hsu PC, Kadlubar SA, Siegel ER, Rogers LJ, Todorova VK, Su LJ, Makhoul I. Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer PLoS One. 2020 Apr 16;15(4):e0230248._x000D_ 2: Du J, Liu Y, Wu X, Sun J, Shi J, Zhang H, Zheng A, Zhou M, Jiang X. BRD9-mediated chromatin remodeling suppresses osteoclastogenesis through negative feedback mechanism Nat Commun. 2023 Mar 14;14(1):1413._x000D_ 3: Kurata K, Samur MK, Liow P, Wen K, Yamamoto L, Liu J, Morelli E, Gulla A, Tai YT, Qi J, Hideshima T, Anderson KC. BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma Clin Cancer Res. 2023 May 1;29(9):1807-1821._x000D_ 4: Zhu X, Liao Y, Tang L. Targeting BRD9 for Cancer Treatment: A New Strategy Onco Targets Ther. 2020 Dec 24;13:13191-13200._x000D_ 5: Weisberg E, Chowdhury B, Meng C, Case AE, Ni W, Garg S, Sattler M, Azab AK, Sun J, Muz B, Sanchez D, Toure A, Stone RM, Galinsky I, Winer E, Gleim S, Gkountela S, Kedves A, Harrington E, Abrams T, Zoller T, Vaupel A, Manley P, Faller M, Chung B, Chen X, Busenhart P, Stephan C, Calkins K, Bonenfant D, Thoma CR, Forrester W, Griffin JD. BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma Blood Cancer J. 2022 Jul 19;12(7):110._x000D_ 6: Zhang C, Chen L, Lou W, Su J, Huang J, Liu A, Xu Y, He H, Gao Y, Xu D, Li Q. Aberrant activation of m6A demethylase FTO renders HIF2Œ±(low/-) clear cell renal cell carcinoma sensitive to BRD9 inhibitors Sci Transl Med. 2021 Sep 29;13(613):eabf6045._x000D_ 7: Sabnis RW. BRD9 Bifunctional Degraders for Treating Cancer ACS Med Chem Lett. 2021 Nov 6;12(12):1879-1880._x000D_ 8: Feng Y, Cai L, Pook M, Liu F, Chang CH, Mouti MA, Nibhani R, Militi S, Dunford J, Philpott M, Fan Y, Fan GC, Liu Q, Qi J, Wang C, Hong W, Morgan H, Wang M, Sadayappan S, Jegga AG, Oppermann U, Wang Y, Huang W, Jiang L, Pauklin S. BRD9-SMAD2/3 Orchestrates Stemness and Tumorigenesis in Pancreatic Ductal Adenocarcinoma Gastroenterology. 2024 Jan;166(1):139-154._x000D_ 9: Ahmed NS, Gatchalian J, Ho J, Burns MJ, Hah N, Wei Z, Downes M, Evans RM, Hargreaves DC. BRD9 regulates interferon-stimulated genes during macrophage activation via cooperation with BET protein BRD4 Proc Natl Acad Sci U S A. 2022 Jan 4;119(1):e2110812119._x000D_ 10: Wang X, Song C, Ye Y, Gu Y, Li X, Chen P, Leng D, Xiao J, Wu H, Xie S, Liu W, Zhao Q, Chen D, Chen X, Wu Q, Chen G, Zhang W. BRD9-mediated control of the TGF-Œ≤/Activin/Nodal pathway regulates self-renewal and differentiation of human embryonic stem cells and progression of cancer cells Nucleic Acids Res. 2023 Nov 27;51(21):11634-11651. _x000D_ _x000D_ Products Related to BRD9 Antibody Polyclonal can be found at Antibodies

• Short Description :

  Catalog Number: B2016894 (10 µL)

• Weight :

  0.15

• Length :

  2

• Width :

  0.5

• Height :

  0.5

• CAS Number :

  9007-83-4